Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
ANGLE plc: Angle Plc - Announces Parsortix: Dynamic Assessment of Patient Response
Use of Parsortix System Enables a Dynamic Assessment of Patient Response to Treatment in Non-Small Cell Lung Cancer
CTCs harvested by the Parsortix system successfully used to measure the dynamic role of EMT and PD-L1 in patient response to therapy
Findings support ANGLE s plan for the growth of a new pharma services business area using the Parsortix system as a biomarker for cancer drug trials allowing longitudinal monitoring of patients
GUILDFORD, SURREY / ACCESSWIRE / February 8, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the National and Kapodistrian University of Athens (Athens) has published results of a new study undertaken in non-small cell lung cancer (NSCLC). This study demonstrates the utility of ANGLE s Parsortix